In the high-stakes world of biotech, speed can mean the difference between a missed breakthrough and a life-saving drug. While artificial intelligence has changed areas like genomics and robotics have accelerated lab processes, one critical piece of the drug discovery pipeline has remained painfully outdated that is its high-content imaging.
Despite advances elsewhere, researchers still spend hours or even days waiting for cellular imaging data to be processed and analyzed.
That’s the problem Araceli Biosciences is here to solve. The Portland-based biotech startup is on a mission to blow up the industry’s biggest bottleneck, and it's doing it with a next-generation platform that fuses ultra-fast imaging with real-time AI-powered analysis. With $11.2 million in fresh funding
Translucent AI Targets Financial Pain Points of Healthcare Providers
Mukundan Sivaraj
